Proverb Announces First Patient Dosing in Phase 1 Study of Muzastotug in Combination with Incyte INCA33890 in Patients with Microsatellite Stable Colorectal Cancer.
Proverb Announces First Patient Dosing in Phase 1 Study of Muzastotug in Combination with Incyte INCA33890 in Patients with Microsatellite Stable Colorectal Cancer.
Want to see every report in real time?
Hundreds of sources worldwide, translated into your language, with alerts for what matters to you.
Sign up free Already have an account? Log in